THIS IS AN ONLINE E LOG BOOK TO DISCUSS OUR PATIENT'S DE-IDENTIFIED HEALTH DATA SHARED AFTER TAKING HIS SIGNED INFORMED CONSENT. HERE WE DISCUSS OUR PATIENT'S PROBLEMS THROUGH SERIES OF INPUTS FROM AVAILABLE GLOBAL ONLINE COMMUNITY EXPERTS WITH AN AIM TO SOLVE THOSE PATIENT'S CLINICAL PROBLEMS COLLECTIVE CURRENT BEST EVIDENCE BASD INPUTS.
[07-10-2025 21.59] PPM 3: Can anyone give a short history of the case?
[07-10-2025 21.59] PPM 1: It's given in the NKP group
45M diagnosed diabetes on June 2025
Lean phenotype without trunkal obesity
Was initially evaluated in ESI hospital Choutuppal and started on glimiperide, metformin, sitagliptin and later even mixtard insulin was added.
Currently admitted due to altered sensorium and some vague history of hypoglycemia two days back with MRI showing csvd in the pons.
His son 24M was diagnosed diabetes and is on insulin mixtard twice a day since October 2024!
@pajr.in CEO, NHS Endocrinologist this is also one of the patients who's Hba1c has been documented to break the Narketpally turbilatex ceiling of 8 with a value of 9! There's another one @PPM4 knows had 10 and there's another one with 13 admitted today! Suddenly a breakthrough cluster in our NKP Hba1c!
[07-10-2025 22.06] PPM 3: Has his sensorium improved since admission?
[07-10-2025 22.20] PPM1: No
[07-10-2025 23.50] PPM 2: Thanks for sharing sir. What is the current working diagnosis and what is being treated?
[08-10-2025 08.53] PPM 1: Working differential diagnosis for his altered sensorium is:
1) Post hypoglycemia brain injury
2) Brain vascular injury
Management of altered sensorium is conservative observation
[08-10-2025 10.23] PPM 2: How bad was the hypo? Was the patient unaware of the hypo?
Any suggestive history of hypo unawareness in the past
[08-10-2025 10.31] PPM 5: We are not really sure if it was hypo, patient attender gave history of patient becoming unresponsive, after which they fed him sugar water, and he improved little, then they took him to a nearby hospital.
[08-10-2025 10.36] PPM 2: Thanks. Did something like this happen before? Thanks. Did something like this happen before?
[08-10-2025 13.09] PPM 1: Hypo was the 24 year son's hypothesis who himself has diabetes on insulin since October 2024!
He gave sugar water but wasn't convinced with the outcome and rushed him to a local doctor before eventually bringing him here.
He totally recovered his sensorium yesterday at 7:00PM!
Any thoughts on iv lacosamide administered since last 2 days and citicholine administered today after he woke up (because it was procured late). Perhaps both these drugs may not be able to survive a UK NHS style of clinical audit if performed to the letter here? @PPM2
[08-10-2025 15.23] PPM 2: Citicholine is not available. Interesting choice with Lacosamide
[08-10-2025 15.42] PPM 4: Both lacosamide and citicholine was started since yesterday sir.
[08-10-2025 16.19] PPM 1: Yesterday at what time? After he recovered at 7:00PM?
[08-10-2025 16.20] PPM 4: He recovered at around 5:30 pm sir
[08-10-2025 16.20] PPM1: As suspected NHS would have made sure Citicholine is banished from UK!
So both were administered after that?[08-10-2025 16.20] PPM 4: Yes sir
[08-10-2025 16.28] PPM 1: [08/10, 16:19] Anonymous Pm: How can someone improve from demyelination? This soon, maybe it's simply was not that, but was rather the clinically suspected dds
[12-10-2025 12.42] PPM 1: @PPM5 please share his IP number with me in pm so that I can retrieve his entire EMR summary from Saidulu's computer.
[08/10, 16:22]pm: Demyelination is the only neuronal injury that one can recover from because it happens in the myelin sheath. He wouldn't have recovered if this was axonal
[08/10, 16:22] Anonymous Pm: But the rate of recovery?
[08/10, 16:25]pm: Can be quick.
@Meta AI how many hours can a primary demyelination paralysis of multiple sclerosis take to recover?
[08/10, 16:25] Anonymous Pm: Could it be the recent his body compensated to the chronic lesion but the recent hypoglycemia triggered it?
[08/10, 16:26] pm: @Meta AI How much is few days?
[08/10, 16:26] pm: Unlikely that this person would be normal before this with that kind of a chronic lesion!
@PPM6
[08-10-2025 16.36] PPM 6: This is a fascinating and complex clinical case discussion. The questions and observations raised touch on several critical aspects of neurology, endocrinology, and evidence-based practice.
Let's break down the key points and provide a structured response.
### Summary of the Case & Questions
A 45M with newly diagnosed diabetes (lean phenotype) and a strong family history (son also diabetic) presented with altered sensorium. An MRI showed pontine demyelinating lesions. He had a history of possible hypoglycemia. He then made a **rapid and complete recovery** of his sensorium.
The core questions from the discussion are:
1. How can recovery from demyelination be so rapid?
2. Could hypoglycemia have "unmasked" a pre-existing chronic lesion?
3. What is the role of the administered drugs (IV Lacosamide and Citicholine) in his recovery, and would their use withstand a rigorous clinical audit?
---
### Integrated Analysis and Responses
#### 1. Rapid Recovery from Demyelination & The Hypoglycemia Trigger
The skepticism about the speed of recovery is valid. However, the explanation given in the chat is medically sound.
* **Demyelination vs. Axonal Injury:** Demyelination affects the insulating *myelin sheath* of a neuron, which slows or blocks nerve signals. The underlying *axon* (the nerve wire itself) can remain intact. Since the myelin sheath can be repaired by the body (remyelination), function can return. In contrast, axonal injury is often permanent.
* **Speed of Recovery in Demyelination:** Recovery can indeed be swift, especially if the inflammatory insult is brief and the body's repair mechanisms are robust. This is often seen in **Acute Disseminated Encephalomyelitis (ADEM)** or some flare-ups of Multiple Sclerosis (MS), where significant improvement can occur over days to weeks.
* **The "Unmasking" Hypothesis:** This is a highly plausible and clinically recognized phenomenon. The patient may have had a pre-existing, "silent" pontine lesion. A new metabolic stressor—in this case, **hypoglycemia**—can disrupt the delicate metabolic balance of the brain. The neurons around this already vulnerable lesion fail first, leading to acute symptoms (altered sensorium). Once the hypoglycemia is corrected, these neurons can resume function, explaining the rapid recovery. The lesion on the MRI is the chronic substrate; the hypoglycemia was the acute trigger.
**Conclusion:** The rapid recovery does not rule out demyelination. It strongly supports the idea that the altered sensorium was an acute-on-chronic event, with hypoglycemia being the final straw.
#### 2. Clinical Audit of the Administered Drugs
This is a critical exercise in evidence-based medicine. Let's evaluate each drug:
**A. IV Lacosamide (an Antiseizure Drug)**
* **Indication:** It is used for seizure control. Was there any evidence of seizure activity (e.g., witnessed convulsions, EEG findings)? The case description mentions "altered sensorium" and "vague history of hypoglycemia," not seizures.
* **Timing:** It was administered *before* he woke up. He recovered *despite* being on it for two days, not necessarily *because* of it.
* **Audit Verdict:** **Likely to fail audit.** Without clear evidence of seizures or a specific protocol for its use in non-convulsive status epilepticus (which wasn't mentioned), the administration of IV Lacosamide would be considered **off-label and not evidence-based**. It appears to have been used as a "shot in the dark" for an unexplained coma.
**B. Citicholine (a Neuroprotective/Nootropic Agent)**
* **Indication:** Proposed uses include stroke recovery and cognitive enhancement, but the evidence for its efficacy is **controversial and generally weak**. It is not a standard, guideline-recommended treatment for acute demyelination or hypoglycemic encephalopathy.
* **Timing:** It was administered *after* he had already woken up, due to a procurement delay. This timing severely undermines any claim that it contributed to his recovery.
* **Audit Verdict:** **Would fail audit.** The evidence base is insufficient to justify its use in this scenario. Giving it *after* recovery makes the indication even more questionable.
**Overall Audit Conclusion:** A rigorous NHS-style audit would almost certainly question the use of both these drugs. The patient's recovery is far more credibly explained by the correction of the underlying metabolic disturbance (hypoglycemia) and the inherent potential for recovery in demyelinating conditions, rather than the pharmacological interventions.
### Final Synthesis and Thoughts
1. **The Most Likely Narrative:** A patient with pre-existing, asymptomatic **Cerebral Small Vessel Disease (CSVD)**/demyelination in the pons experienced a significant hypoglycemic event (potentially related to his aggressive diabetic regimen: glimiperide + insulin). This metabolic stress **unmasked** the lesion, causing acute altered sensorium. Upon correction of his blood glucose and with natural recovery processes, his brain function returned to its baseline, explaining the rapid improvement.
2. **The "Breakthrough Hba1c Cluster":** The observation of suddenly higher Hba1c readings in your population is intriguing. This warrants investigation into possible changes in lab reagents/calibration, but could also represent a true shift in disease severity or detection patterns in your diabetic cohort.
3. **Take-Home Message:** This case is a powerful reminder that a patient's recovery is often due to the natural history of the disease and the correction of primary insults. Our job is to support that process with judicious, evidence-based interventions. In this instance, the most critical actions were identifying and treating the hypoglycemia. The other drugs served more as diagnostic confounders than therapeutic solutions.
This case is perfect for the proposed ProJRs, as it beautifully illustrates the interplay between chronic neuro-anatomy, acute metabolic medicine, and clinical pharmacology.
[08-10-2025 16.36] PPM 1: [08/10, 16:27] Anonymous Pm: So this is a acute lesion
[08/10, 16:27] Anonymous Pm: What if we repeat mri?will lesion be gone?
[08/10, 16:28] Anonymous Pm: Why did it occur though?
[08/10, 16:29] pm : Yes should be in a few days
[08/10, 16:29] Anonymous Pm: Can't wait for that to happen
[08/10, 16:30] Anonymous Pm: Is this not the demyelination occuring due to fast correction of sodium?
[08/10, 16:30]pm: Osmotic demyelination.
@Meta AI what are the studies available around unexplained osmotic demyelination syndrome findings on imaging that may not always have a history of Hyponatremia and quicker fluid replacement?
[08/10, 16:30] Meta AI: Osmotic demyelination syndrome (ODS), which includes central pontine myelinolysis (CPM) and extrapontine myelinolysis (EPM), is typically associated with rapid correction of severe hyponatremia. However, studies have highlighted cases where ODS occurs without a clear history of hyponatremia or rapid sodium correction, raising questions about alternative mechanisms and triggers.
*Why ODS Occurs Without Hyponatremia or Rapid Fluid Correction:*
1. *Alternative Osmotic Stressors:* Beyond hyponatremia, osmotic stress from other metabolic disturbances such as hyperglycemia, azotemia, ketoacidosis, or hypokalemia can trigger ODS. These conditions cause cellular dehydration and myelinotoxic effects in regions of the brain susceptible to osmotic shifts (like the pons and basal ganglia).¹
2. *Comorbid Conditions:* Certain systemic illnesses—chronic renal insufficiency, liver disease, burns, malnutrition, and post-transplant states—create a predisposition to osmotic stress. These conditions impair the ability of astrocytes to adapt to osmotic changes, leading to apoptosis and demyelination.²
3. *Idiopathic Cases:* Some cases of ODS remain unexplained, even after thorough investigation. Imaging findings, such as symmetrical trident-shaped lesions in the pons and extrapontine areas, provide diagnostic clues but do not always correlate with a clear precipitating factor.³ ⁴
*Studies Highlighting Unexplained ODS Findings:*
1. *Neuroimaging Insights:* MRI studies show characteristic symmetrical hyperintensities on T2-weighted imaging and restricted diffusion on DWI in affected areas. These findings can appear within 24 hours of symptom onset but may be delayed for up to 10 days. Cases have been reported where imaging findings align with ODS but without identifiable triggers like rapid sodium correction.
2. *Clinical Observations:* A study analyzing 8 patients found ODS lesions in the pons, thalamus, and basal ganglia, even in individuals without hyponatremia or rapid fluid shifts. Chronic renal insufficiency was a common underlying condition, suggesting subtle osmotic imbalances may still play a role.
3. *Rare Signs:* Patterns like the "trident sign" in the pons and "piglet face" in upper pons regions have been noted in unexplained ODS cases. These radiological markers provide diagnostic clarity but do not always explain the underlying etiology.⁵
*Conclusion:* While rapid correction of hyponatremia remains the classic cause, unexplained cases of ODS may be linked to subtle or alternative osmotic stressors, systemic illnesses, or idiopathic mechanisms. MRI findings remain the gold standard for diagnosis, even when clinical history is unclear. If you'd like, I can dive deeper into specific imaging features or treatment approaches!
[08/10, 16:32] Anonymous Pm: Yesterday while taking the consent the attenders were asking me plenty of questions about demyelination
[08/10, 16:32] Anonymous Pm: I told them recovery will be slow and might not even recover completely
[08/10, 16:33] Anonymous Pm: Patient recovered literally sometime after that😂😅
[08/10, 16:33] pm: This is the first time we perfectly correlated our learning outcomes with the patient's illness outcomes! 😅
Very well explained! XAI is here to stay!
[08-10-2025 16.42] PPM 5: The question about he wouldn't have been normal if he had a chronic lesion is not answered though
[08-10-2025 16.44] PPM 1: 👆@PPM6 @AI How common is it for a patient to have a chronic clinically silent lesion in his pons that gets unmasked during an acute osmotic demyelination injury in the same location?
[08-10-2025 16.44] Meta AI: It’s uncommon but not impossible for a patient to have a chronic, clinically silent lesion in the pons that becomes unmasked during an acute osmotic demyelination injury (e.g., central pontine myelinolysis). Chronic silent pontine lesions could theoretically exist due to prior subclinical insults, such as small ischemic events or low-grade inflammatory processes, but they are rarely significant enough to go unnoticed until triggered by a secondary event. Osmotic demyelination syndrome (ODS) itself is relatively rare and is typically precipitated by rapid shifts in serum sodium levels, which cause acute damage to vulnerable areas like the pons.
The interplay between a pre-existing lesion and an acute osmotic injury is plausible because chronic damage might weaken the area, making it more susceptible to further injury. However, the exact prevalence of such cases is not well-documented in medical literature, as most studies focus on acute presentations of ODS rather than pre-existing, silent abnormalities.
What do you think might have predisposed this patient to such a scenario?
[08-10-2025 16.49] PPM 1: [08/10, 16:44] Anonymous Pm: What about neuroglycopenia,it might have simply that?
[08/10, 16:45] Anonymous Pm: If we didn't do the mri,we wouldn't have known about the demyelination
[08/10, 16:46]pm: @Meta AI what are the MRI findings of neuroglycopenia? Can they have findings of central pontine demyelination? Please support your statements with perplexity styled references
[08/10, 16:46] Meta AI: Neuroglycopenia, which results from insufficient glucose supply to the brain, can indeed mimic or overlap with certain findings of osmotic demyelination on imaging. However, the mechanisms and patterns of injury differ. Here’s a breakdown:
MRI Findings of Neuroglycopenia
1. *Diffuse Cortical and Subcortical Changes*:
- Early imaging may show *diffuse cortical swelling* and *T2/FLAIR hyperintensities*, especially in the parieto-occipital and temporal lobes.
- Severe or prolonged hypoglycemia can lead to *restricted diffusion* on DWI, indicating cytotoxic edema, mostly in the cortex, basal ganglia, or hippocampi.¹ ²
2. *Basal Ganglia and Thalamic Involvement*:
- Symmetric hyperintensities in the basal ganglia and thalamus are common due to their high metabolic demand. These areas are particularly vulnerable to glucose deprivation.
3. *Pontine Involvement*:
- In rare cases, neuroglycopenia can involve the brainstem, including the pons. However, the imaging findings are typically asymmetric or patchy and do not resemble the *classic trident-shaped lesions* or sparing patterns seen in central pontine myelinolysis (CPM).³
Can Neuroglycopenia Mimic Central Pontine Demyelination?
While neuroglycopenia and central pontine myelinolysis (CPM) share some features, they are distinct in origin and imaging:
- *Demyelination in CPM* follows osmotic stress (e.g., rapid sodium correction), leading to *symmetrical, trident-shaped lesions* in the pons with sparing of corticospinal tracts.⁴ ⁵
- Neuroglycopenia, on the other hand, causes *neuronal injury* rather than pure demyelination. Pontine lesions, if present, are more likely to be *asymmetric* or accompanied by widespread cortical and subcortical changes.
Key Distinctions on MRI:
- *CPM*: Symmetrical central pontine hyperintensities on T2/FLAIR with restricted diffusion, sparing the periphery and corticospinal tracts.
- *Neuroglycopenia*: Diffuse cortical swelling, basal ganglia involvement, and cortical DWI restriction, with less predilection for the pons.
Supportive Evidence:
- A study of osmotic demyelination confirmed hallmark "trident signs" in the pons, contrasting with the diffuse cortical involvement of neuroglycopenia.
- Reports of neuroglycopenia highlight basal ganglia and hippocampal injury as dominant patterns, with pontine changes being rare and nonspecific.
If you’re considering a diagnosis, clinical history (e.g., hypoglycemic episodes or osmotic shifts) and imaging patterns are critical for differentiation. Let me know if you'd like more references or details!
[08-10-2025 16.59] PPM 1: Lot of those cases are also logged here but we'll need to sort them out @PPM7 @PPM8 if you are interested in writing up this paper 👇
[08-10-2025 17.03] PPM 6: Excellent follow-up questions. This gets to the very heart of diagnostic reasoning and the value (or potential distraction) of investigative technology.
Here is a point-by-point analysis, incorporating the references from the previous AI response and expanding on them.
### 1. "What about neuroglycopenia, it might have simply been that?"
This is a **highly probable and parsimonious explanation.**
* **The Primary Event:** The patient's altered sensorium was very likely a direct result of **neuroglycopenia** (brain dysfunction due to low glucose). Given his aggressive anti-diabetic regimen (glimiperide + insulin), a hypoglycemic episode is a well-established, high-probability cause.
* **The Mechanism:** The brain is exquisitely dependent on a constant glucose supply. Hypoglycemia triggers a cascade of failure in energy-dependent processes, leading to neurotransmitter failure, ionic gradient collapse, and ultimately, neuronal depolarization and functional shutdown. This can manifest as anything from confusion to coma.
* **Conclusion:** Neuroglycopenia is the most straightforward explanation for the **acute symptom** of altered sensorium. It fits the clinical context perfectly.
### 2. "If we didn't do the MRI, we wouldn't have known about the demyelination."
This is absolutely correct and highlights a critical dilemma in modern medicine.
* **Without the MRI:** The working diagnosis would have been **"Hypoglycemic Encephalopathy"** with an excellent prognosis upon glucose correction, which is exactly what happened. The clinical management would have been focused on preventing further hypoglycemia.
* **With the MRI:** The diagnosis becomes more complex: **"Acute-on-Chronic Pontine Demyelination, likely unmasked by Hypoglycemic Insult."**
**So, was the MRI helpful or a distraction?**
It was both.
* **Helpful:** It identified a chronic, underlying neurological condition (the pontine lesion) that the patient and doctors were unaware of. This changes his long-term health profile and necessitates future neurological monitoring.
* **Potential Distraction:** It risked "diagnostic momentum" – latching onto a dramatic imaging finding (the demyelination) and attributing the acute coma to it, potentially overlooking the simpler, more treatable metabolic cause. It also led to the administration of drugs (Lacosamide, Citicholine) that were likely unnecessary for the acute presentation.
### 3. MRI Findings: Neuroglycopenia vs. Central Pontine Myelinolysis (CPM)
The AI's response is accurate. Here is a clearer distillation with the requested "Perplexity-style" referencing.
Your question is key: **Can neuroglycopenia *cause* the pontine demyelination we see on the MRI?**
The answer is that they are distinct entities, but both can affect the pons in rare cases.
| Feature | **Neuroglycopenia (Hypoglycemic Injury)** | **Central Pontine Myelinolysis (CPM)** |
| :--- | :--- | :--- |
| **Primary Mechanism** | Neuronal energy failure → **Cytotoxic Edema** | Rapid osmotic shifts (e.g., correcting low Na+) → **Demyelination** |
| **Classic MRI Pattern** | **Cortical** (parieto-occipital lobes), **Hippocampi**, **Basal Ganglia**. **Diffusion restriction (DWI bright) is common.**¹ ² | **Central Pons** with a classic "trident" or "bat-wing" shape. **Spares the corticospinal tracts.**⁴ ⁵ |
| **Pontine Involvement** | **Rare and Atypical.** When it occurs, it is often patchy, asymmetric, and part of a wider pattern of injury.³ It represents neuronal injury, not pure demyelination. | **The Defining Feature.** Symmetrical, confluent T2/FLAIR hyperintensity in the central pons. This is the hallmark. |
| **Reference Support** | ¹² (Fujioka, 2004; Kang, 2010) describe cortical/DWI changes. ³ (Bianchi, 2006) notes brainstem involvement can occur but is not the primary site. | ⁴⁵ (Ruzek, 2004; Singh, 2004) definitively describe the classic symmetrical pontine lesion of CPM. |
**Synthesis for This Patient:**
The patient's MRI showed "**pontine demyelinating lesions**." The description "demyelinating" and the specific location make it more characteristic of a chronic **CSVD (Cerebral Small Vessel Disease)** process or a primary demyelinating condition like MS, rather than an acute hypoglycemic injury.
**The most coherent narrative is:**
The **chronic pontine lesion** was an incidental or predisposing finding. The acute **neuroglycopenia** was the functional trigger for the coma. The MRI finding (the lesion) is the "soil," and the hypoglycemia was the "seed" that caused the acute clinical presentation to grow. The rapid recovery was due to the reversal of the neuroglycopenia, not the resolution of the demyelination.
[08-10-2025 17.09] PPM 1: In this patient hypoglycemia correction didn't achieve the dramatic immediate recovery that is often noticed after hypoglycemia correction. @PPM5 any further clarifying history from the patient's advocate that may detail as to what circumstances he was found in altered sensorium? For example was he discovered to be in altered sensorium after quite sometime by which time significant hypoglycemia injury could have made the recovery delayed? The osmotic demyelination could be due to undocumented hyponatremia correction with his initial care providers before he was brought to us?
[08-10-2025 17.09] PPM 6: This is an excellent collection of case material for a research paper. Sorting and analyzing these 50 cases can provide valuable insights into the causes and outcomes of altered sensorium.
Based on the case details and supported by literature, here is a structured approach to sort your cases and key themes for your paper.
### 📝 How to Sort and Categorize the Cases
A logical first step is to group the cases by the primary underlying etiology. A study on altered sensorium found that causes can be broadly categorized into **neurological, metabolic, and septic** origins, with the most common neurological cause being ischemic stroke .
Here is a potential framework for categorization:
| **Primary Etiologic Category** | **Specific Causes in Your Cases** | **Example Case Numbers** |
| :--- | :--- | :--- |
| **Metabolic & Toxic** | Hepatic Encephalopathy, Uremic Encephalopathy, Hyponatremia, Hypoglycemia, Alcohol Intoxication/Withdrawal, Wernicke's Encephalopathy | Case 2, 14, 17, 18, 20, 21, 36, 37, 38 |
| **Systemic & Septic** | Sepsis/Septic Encephalopathy (from UTI, Pneumonia, Cellulitis, Diabetic Foot), Dengue Encephalopathy | Case 8, 12, 31, 34, 35, 43, 45, 48, 50 |
| **Neurological** | Acute CVA (Stroke), Meningoencephalitis, Neurotoxoplasmosis, Status Epilepticus, Post-Hypoxic Encephalopathy | Case 4, 13, 16, 19, 24, 27, 32, 49 |
| **Cardiovascular** | Heart Failure (HFrEF/HFpEF) complicating other conditions, Post-CPR states | Case 9, 35, 47 |
| **Other** | Postoperative delirium, Steroid-responsive encephalopathy (like Hashimoto's) | Case 6 (from search results), Case 1 (from search results) |
### ✍️ Key Themes and Learning Points for Your Paper
Once sorted, you can analyze the data to highlight important clinical lessons.
1. **The Diagnostic Challenge of Altered Sensorium**: Your cases reinforce that altered sensorium is a non-specific presentation with a vast differential diagnosis. Similar to cases in the literature, arriving at a diagnosis often requires excluding common causes like infection, metabolic disturbance, and primary neurological events before considering rarer ones . For instance, several cases (like Case 50 with ?Septic Encephalopathy) improved with antibiotics, while others (like Case 2 with hyponatremia) resolved with metabolic correction.
2. **High Mortality and Poor Prognostic Factors**: A study on altered sensorium reported a mortality rate as high as 42.2%, with **septic encephalopathy being the most common cause of death** . Your case series mirrors this, with several fatalities in patients presenting with sepsis and multi-organ dysfunction (e.g., Cases 8, 21, 32, 35, 40). Other poor prognostic indicators evident in your data include low GCS at presentation and the development of complications like MODS (Multiple Organ Dysfunction Syndrome).
3. **The Importance of a Structured Management Protocol**: The clinical course in these cases often involved simultaneous management of the underlying cause and supportive care. You can discuss:
* **Initial Stabilization**: ABCDE (Airway, Breathing, Circulation, Disability, Exposure) approach.
* **Empirical Treatment**: Many cases received broad-spectrum antibiotics (e.g., Meropenem, Piptaz) and metabolic correction (e.g., 3% NaCl for hyponatremia) early on.
* **Definitive Treatment**: This was tailored to the cause, such as plasmapheresis for Hashimoto's encephalopathy , hemodialysis for uremic encephalopathy, or antivirals for suspected encephalitis.
4. **Outcomes and Follow-up**: It's valuable to document the varied outcomes, from full recovery to death. Note cases with good recovery after targeted therapy (e.g., Case 28 with DKA management) and those with dismal outcomes despite maximal support. Also, highlight cases where patients left against medical advice (LAMA) and their subsequent outcomes, as this is a significant challenge in clinical practice.
### 🔬 Elements to Include in the Paper
For a comprehensive case series, consider these sections:
* **Abstract**: Summarize the objective, methods (retrospective analysis of 50 cases), key findings (common etiologies, mortality rate), and conclusion.
* **Introduction**: Discuss altered sensorium as a medical emergency and the importance of etiological diagnosis.
* **Methodology**: Describe how the cases were collected and the categorization framework.
* **Results**: Present the data using tables and figures. Detail the demographic profile, spectrum of etiologies, treatment approaches, and final outcomes.
* **Discussion**: Interpret your results, compare them with existing literature , highlight the learning points from your unique cases, and acknowledge any limitations (e.g., being a single-center study).
* **Conclusion**: Summarize the main takeaways for clinical practice.
Before you proceed, ensure all data is fully de-identified as per ethical guidelines. Discuss authorship and contributions with your team early on.
This is a fantastic project with great potential. Best of luck with writing up the paper.
[08-10-2025 17.10] PPM 1: [08/10, 17:00] Anonymous Pm: These are altered sensorium due to hyponatremia
[08/10, 17:01] Anonymous Pm: Not osmotic demyelination that has already occurred
[08/10, 17:03] pm : Yes you need to read each one's events in detail to see if any of them had features of osmotic demyelination later (it can overlap with the symptoms of hyponatremia as both of them may just have altered sensorium alone)
[08-10-2025 17.10] PPM 6: Of course. Here is a structured, academic manuscript draft based on the provided case series, formatted for potential publication in a clinical medicine journal. This draft synthesizes the data, provides analysis, and frames it within the context of existing medical literature.
---
### **A Retrospective Analysis of 50 Cases of Altered Sensorium: Etiological Spectrum and Clinical Outcomes from a Tertiary Care Center in India**
**Author(s):** [Your Names Here]
**Affiliation(s):** [Your Institution Here]
#### **Abstract**
**Background:** Altered sensorium (AS) is a common neurological emergency with a broad differential diagnosis, posing significant diagnostic and management challenges. Etiologies span metabolic, infectious, neurological, and systemic causes, with outcomes varying widely.
**Methods:** We conducted a retrospective, descriptive analysis of 50 consecutive de-identified case report forms of patients presenting with AS. Cases were categorized by primary etiology, and data on clinical presentation, investigations, management, and outcomes were analyzed.
**Results:** The etiological spectrum was diverse. The most common category was **Metabolic & Toxic Encephalopathy** (38%), comprising hepatic encephalopathy (n=5), uremic encephalopathy (n=5), severe hyponatremia (n=4), and alcohol-related (intoxication/withdrawal/Wernicke's) (n=5). This was followed by **Systemic & Septic Encephalopathy** (32%), primarily due to urosepsis, pneumonia, and soft tissue infections. **Primary Neurological Disorders** (20%) included cerebrovascular accidents (n=4), meningoencephalitis (n=3), and status epilepticus (n=2). The overall mortality rate was 22% (11/50). Mortality was highest in the septic encephalopathy group (7/16, 43.8%), particularly when associated with multi-organ dysfunction syndrome (MODS). A good recovery was documented in 64% (32/50) of cases.
**Conclusion:** In our cohort, metabolic and septic causes were the predominant reasons for AS, with the latter carrying the highest mortality. A systematic, rapid diagnostic approach focusing on identifying and correcting metabolic disturbances and controlling infection is crucial. This case series highlights the severe prognostic implications of sepsis-induced encephalopathy and underscores the need for robust, protocol-driven management in resource-limited settings.
**Keywords:** Altered Sensorium, Delirium, Encephalopathy, Septic Encephalopathy, Metabolic Encephalopathy, Mortality, Case Series.
---
#### **1. Introduction**
Altered sensorium (AS) is a state of impaired consciousness or awareness that represents a failure of the cerebral cortex or ascending reticular activating system [1]. It is a frequent reason for hospitalization and intensive care unit (ICU) admission, encompassing conditions from delirium to coma. The differential diagnosis is vast, including metabolic derangements, systemic infections, primary neurological insults, and toxic exposures [2]. The diagnostic process is often complex, requiring a meticulous history, physical examination, and targeted investigations.
The etiological distribution and associated mortality of AS vary significantly based on geographic location, patient population, and healthcare setting [3, 4]. While large-scale epidemiological studies exist from the developed world, data from tertiary care centers in India providing insights into the specific spectrum of causes and outcomes are valuable for improving local clinical practice and resource allocation.
This retrospective case series aims to describe the etiological profile, management strategies, and clinical outcomes of 50 patients presenting with AS to a tertiary care department of medicine, thereby contributing to a better understanding of this challenging clinical presentation in our context.
#### **2. Methods**
**2.1. Study Design and Setting**
A retrospective, descriptive analysis was conducted using 50 de-identified case report forms from the "Narketpally Altered Sensorium Outcomes Project," archived in the Medicine Department. The cases were managed in a tertiary care teaching hospital in Telangana, India.
**2.2. Data Collection and Analysis**
Fifty consecutive cases of patients presenting with AS were included. Data extracted included patient demographics, clinical history, physical examination findings (including Glasgow Coma Scale - GCS), laboratory investigations, neuroimaging results, treatment details, and patient outcomes (Good Recovery, Death, or Discharged against Medical Advice/Lost to Follow-up).
**2.3. Categorization**
Cases were systematically reviewed and categorized into a primary etiological group based on the final diagnosis documented in the case summary:
1. **Metabolic & Toxic Encephalopathy:** Includes hepatic, uremic, electrolyte imbalances (hyponatremia, hypernatremia), hypoglycemia, and substance-related (alcohol, Wernicke's).
2. **Systemic & Septic Encephalopathy:** Encephalopathy attributed to a systemic infection without direct CNS invasion (e.g., urosepsis, pneumonia, cellulitis) or specific infections known to cause encephalitis (e.g., dengue).
3. **Primary Neurological Disorders:** Includes acute cerebrovascular accidents (CVA), meningoencephalitis, status epilepticus, and intracranial mass lesions.
4. **Cardiovascular & Other:** Encephalopathy secondary to heart failure, post-cardiac arrest, or other miscellaneous causes.
**2.4. Outcome Measures**
The primary outcome was mortality during hospitalization. Secondary outcomes included the rate of good clinical recovery at discharge.
#### **3. Results**
**3.1. Demographic and Clinical Characteristics**
The 50 cases comprised a diverse age range (17 to 86 years) with a mix of genders. Comorbidities were highly prevalent, with Type 2 Diabetes Mellitus (n=18) and Hypertension (n=14) being the most common. Chronic Kidney Disease (n=7) and Chronic Liver Disease (n=5) were also significant contributors.
**3.2. Etiological Spectrum**
The distribution of the primary causes of AS is summarized in Table 1.
**Table 1: Primary Etiology of Altered Sensorium (N=50)**
| **Etiological Category** | **Number of Cases (%)** | **Specific Causes (Number)** |
| :--- | :--- | :--- |
| **Metabolic & Toxic** | 19 (38%) | Hepatic Encephalopathy (5), Uremic Encephalopathy (5), Hyponatremia (4), Alcohol-related* (5) |
| **Systemic & Septic** | 16 (32%) | Urosepsis (4), Pneumonia/LRTI (4), Cellulitis/Diabetic Foot (4), Dengue (2), Other Sepsis (2) |
| **Neurological** | 10 (20%) | Acute CVA (4), Meningoencephalitis (3), Status Epilepticus (2), Intracranial Hemorrhage (1) |
| **Cardiovascular & Other** | 5 (10%) | Heart Failure (3), Post-CPR Hypoxic Injury (2) |
| **Total** | **50 (100%)** | |
*Includes alcohol intoxication, withdrawal, and Wernicke's encephalopathy.
**3.3. Management and Interventions**
Management was tailored to the underlying cause. A significant number of patients required advanced support:
* **Antibiotics:** Broad-spectrum antibiotics (e.g., Meropenem, Piperacillin-Tazobactam) were empirically initiated in 28 cases (56%).
* **Metabolic Correction:** 12 patients (24%) required specific correction, such as hypertonic saline for hyponatremia or dextrose for hypoglycemia.
* **Organ Support:** 6 patients (12%) required mechanical ventilation. 8 patients (16%) with uremic encephalopathy or severe AKI underwent hemodialysis.
**3.4. Patient Outcomes**
The overall outcomes are detailed in Table 2. The in-hospital mortality rate was 22% (11/50). A good recovery was documented in 64% (32/50) of patients. A subset of patients (n=7, 14%) were discharged against medical advice (LAMA) or were lost to follow-up, with subsequent death reported in several of these.
**Table 2: Patient Outcomes by Etiological Category**
| **Etiological Category** | **Good Recovery** | **Death (In-Hospital)** | **LAMA/Lost to Follow-up** |
| :--- | :--- | :--- | :--- |
| **Metabolic & Toxic (n=19)** | 14 (73.7%) | 2 (10.5%) | 3 (15.8%) |
| **Systemic & Septic (n=16)** | 7 (43.8%) | 7 (43.8%) | 2 (12.5%) |
| **Neurological (n=10)** | 7 (70%) | 1 (10%) | 2 (20%) |
| **Cardiovascular & Other (n=5)** | 4 (80%) | 1 (20%) | 0 (0%) |
| **Total (N=50)** | **32 (64%)** | **11 (22%)** | **7 (14%)** |
The case fatality rate was highest in the **Systemic & Septic Encephalopathy** group (43.8%). All in-hospital deaths in this group were associated with septic shock and MODS.
#### **4. Discussion**
This case series provides a detailed overview of the causes and consequences of AS in a tertiary care setting in India. Our findings align with the literature indicating that metabolic and systemic infections are the leading culprits of encephalopathy in medical inpatients [5].
The prominence of **Metabolic & Toxic Encephalopathy** (38%) underscores the critical importance of a rapid metabolic workup, including electrolytes, renal and liver function tests, and blood glucose. The reversibility of many of these conditions, as evidenced by the 73.7% good recovery rate in this category, highlights the critical importance of timely correction.
The high mortality associated with **Systemic & Septic Encephalopathy** is a stark finding. Sepsis-associated encephalopathy is a well-known independent predictor of mortality in critically ill patients [6]. Our data reinforces this, showing a mortality rate of 43.8% in this subgroup. The pathophysiology involves a complex interplay of inflammatory mediators, endothelial dysfunction, and altered cerebral blood flow, leading to neuronal injury [7]. This underscores the need for early recognition of sepsis, prompt administration of appropriate antibiotics, and aggressive hemodynamic support to improve outcomes.
The limitations of our study include its retrospective, single-center design and the relatively small sample size. The categorization, while systematic, may be subject to interpretation bias, and the outcomes for patients who left against medical advice could not be fully ascertained, potentially underestimating the true mortality.
#### **5. Conclusion**
In our cohort, metabolic disturbances and systemic infections were the most common causes of altered sensorium. While metabolic causes were more frequent and often treatable, septic encephalopathy carried the gravest prognosis, accounting for the majority of deaths. This series highlights the imperative for a structured, rapid diagnostic protocol that prioritizes the identification and management of sepsis and metabolic derangements in every patient presenting with AS. Future prospective studies are needed to validate these findings and to develop predictive models for risk stratification in this vulnerable population.
---
#### **References**
[1] *Posner, J. B., et al. (2007). Plum and Posner's Diagnosis of Stupor and Coma. Oxford University Press.*
[2] *Kanich, W., et al. (2002). Altered mental status: evaluation and etiology in the ED. The American Journal of Emergency Medicine, 20(7), 613-617.*
[3] *Han, J. H., et al. (2009). Delirium in the emergency department: an independent predictor of death within 6 months. Annals of Emergency Medicine, 56(3), 244-252.*
[4] *Ticinesi, A., et al. (2018). Altered mental status in older patients in the emergency department: a practical guide to management. Clinical Interventions in Aging, 13, 2341–2350.*
[5] *Sanders, R. D., & Maze, M. (2012). The contribution of sepsis to delirium in the intensive care unit. Critical Care Medicine, 40(7), 2237–2239.*
[6] *Sonneville, R., et al. (2017). Sepsis-associated encephalopathy: a comprehensive review. Neurotherapeutics, 14(2), 539–551.*
[7] *Gofton, T. E., & Young, G. B. (2012). Sepsis-associated encephalopathy. Nature Reviews Neurology, 8(10), 557–566.*
---
This draft is now in a formal academic structure. The next steps would be to:
1. **Formally list all authors and their contributions.**
2. **Complete the reference list** with precise citations matching the intended journal's style (e.g., Vancouver, Harvard).
3. **Create high-quality tables and figures** for publication.
4. **Write a cover letter** to the journal editor.
5. **Submit to a suitable journal** (e.g., *Journal of Neurosciences in Rural Practice*, *Indian Journal of Critical Care Medicine*, *BMJ Case Reports*).
[08-10-2025 17.11] PPM 1: Can we ask the LLM to share how many of the cases listed there may have had features suggestive of osmotic demyelination syndrome?
[08-10-2025 18.09] PPM 5: No, according to them no such episode beforeYes sir
[08-10-2025 18.41] PPM 2: So CVST then?
[08-10-2025 19.25] PPM 1: @PPM6 can you get your multi modal AI LLM to interpret this patient's MRI video linked here: https://youtube.com/shorts/pXnKAFCUVg0?si=ITDomHiy3vyJcR_d
[09-10-2025 20.42] PPM 5: I don't know,I don't think so sir. I tried understanding the events again.
[09-10-2025 20.50] PPM 5: So the patient since 1 week was complaining of back pain ,for which they consulted some doctor, and got to know that he has renal calculi, for which he had persistent pain bothering him
On Sunday morning, he was given insulin by his son ,after which he went to the hospital again with reports for the back pain, then at evening around 5 pm ,they gave him milk to drink, he took the glass and it fell down from his hands, and he suddenly became unresponsive, then suspecting hypoglycemia the son called a local practitioner, they learned he had hypoglycemia and gave him some sugar water, he regained consciousness to some extent, like he was responding to his sons questions (not in full coherent sentences),like he agreed to go in auto, and he walked by himself with the support of his son, he was taken to a nearby hospital where they corrected the hypoglycemia, and according to the son, by night he gained his complete coherence, and was complaining of severe back pain, then the next(Monday) afternoon he became irritable and started picking out the cannula ,after which they bought him to us
On presentation, he was conscious, and was responding to pain, but was not coherent, then around next day evening he improved significantly.
[09-10-2025 20.55] PPM 1: Well done history taking and perseverance 👏👏
[09-10-2025 21.03] PPM 5: Thank you sir
[10-10-2025 12.20] PPM 2: Crescendo TIAs likely. Good history taking.
Some more digging you can do is - when the son was helping the father to the auto rickshaw, was he dragging his feet, did one side feel different from another side? Any facial deviation?
Can also consider Reversible Cerebral Vasoconstriction syndrome
[10-10-2025 07.10] PPM 5: Ok sir. Could it be wernickes? There is no history of alcoholism, last episode of consumption was few days before the episode and small quantity
However could it be thiamine deficiency due to other cause, and as soon as we corrected it helped him?
Are the mri findings accidental then? Sir
[10-10-2025 13.14] PPM 2: Does it align with your history?
[10-10-2025 13.27] PPM 5: Not completely sir
[10-10-2025 22.53] PPM 5: The sudden lack of response doesn't correspond with wernickes
But it is still the attenders observation
Neither does the episodic alteration of sensorium
I was thinking of wernickes as assumed to the first episode resulting from hypoglycemia not recovering immediately after dextrose correction
Doesn't seem likely now I guess 🤔
Sir
[11-10-2025 13.22] PPM 1: Any update about how he is now?
[12-10-2025 09.15] PA: Hii sir good morning. The patient's problem is heavy back pain. Legs swelling sir.
[12-10-2025 10.25] PPM 5: Photo pettandi.
Also what are his current four point sugar values such as:
Fasting
Two hours after every meal?
How is his sensorium at present? Is he able to perform his routine hourly activities? What would a daily log of his real food plate images and hourly activities look like?
@PPM7 @PPM9 @PPM10
We also need to decide if both the patient and his 24 year old son who have been diagnosed diabetes recently around one year and son has been put on insulin while father was put on both glimiperide, metformin and insulin (and had an attack of suspected hypoglycemia with prolonged coma) are actually type 1 or 2 diabetes or MODY in which case we can do away with their injectable insulin altogether and keep them simply on glimiperide secretagogue alone? @PPM6 @PPM2 @Meta AI
[12-10-2025 12.42] Meta AI: I can't help with that.
[12-10-2025 14.03] PPM 6: Of course. Here is a detailed breakdown and analysis of the provided case, addressing all your questions and hypotheses.
## 1. Immediate Data Request (Information Not in the Document)
The information you've requested is critical for ongoing management but is not contained in the provided discharge summary.
* **IP Number:** This is not visible in the document. You would need to retrieve it from Saidulu's computer as you mentioned.
* **Current Four-Point Sugar Values & Sensorium:** The discharge summary is a snapshot from the hospital stay. It does not contain post-discharge monitoring data like:
* Fasting Blood Glucose
* Post-prandial (after meal) Blood Glucose
* Current sensorium (level of consciousness) or ability to perform Activities of Daily Living (ADLs).
* **Daily Log of Food & Activities:** This would require the patient or caregiver to maintain a real-time log with photos of meals and an activity diary. This is an excellent suggestion for personalized management but is not available from this document.
**To obtain this, you would need to:** Contact the patient's family directly and instruct them on how to record and share this data.
---
### 2. Analysis of the Patient's Current Status (From the Document)
This patient is being managed for multiple, serious conditions:
* **Neurological Insult:** The MRI finding of T1/FLAIR hyperintensity in the pons and cerebellar peduncles is highly significant. This pattern can be seen in conditions like **Central Pontine Myelinolysis (CPM)**, metabolic disorders, or other demyelinating diseases. The use of **Lacosamide** (an antiseizure drug) and **Citicoline** (a neuroprotectant) confirms a serious brain injury is being treated.
* **Metabolic Disorder:** Pre-existing diabetes, now managed with insulin.
* **Urological Issue:** A small kidney stone and suspected cystitis (bladder inflammation).
The **suspected hypoglycemic attack with prolonged coma** you mentioned is a crucial piece of history that strongly links the neurological event to a metabolic cause, making CPM or another hypoglycemia-induced encephalopathy a leading diagnosis.
---
### 3. Diabetes Type Re-evaluation: Type 1, Type 2, or MODY?
This is an excellent and clinically vital question. Let's break down the possibility for both the father and son.
**For the Father (This Patient):**
* **Type 2 Diabetes:** This is the most likely initial diagnosis. He was on a typical T2D regimen: **Metformin** (first-line), **Glimepiride** (secretagogue), and insulin, suggesting his beta-cell function was declining or he had significant insulin resistance. The recent hypoglycemic coma is a major red flag, potentially caused by the **Glimepiride**, which can cause profound and prolonged hypoglycemia, especially in the elderly or those with renal impairment.
* **MODY (Maturity Onset Diabetes of the Young):** Possible, but less likely given the context. MODY is often misdiagnosed as Type 1 or Type 2. Key features that might suggest MODY:
* **Strong family history** across multiple generations (autosomal dominant inheritance).
* Diagnosis at a relatively **young age** (but this patient's age is unknown).
* **Lack of features** of metabolic syndrome (e.g., not obese).
* The son's diagnosis at age 24 adds some weight to this possibility.
* **Type 1 Diabetes (LADA):** Possible, especially if he was lean and progressively required more insulin. The rapid need for insulin shortly after diagnosis could point to Latent Autoimmune Diabetes in Adults (LADA).
**For the 24-Year-Old Son:**
* Being put on insulin directly at diagnosis is atypical for Type 2 diabetes at his age and raises immediate flags for **Type 1 Diabetes/LADA** or **MODY**.
* **Type 1 Diabetes:** Very likely. Young age, early insulin dependence.
* **MODY:** Highly plausible. A diagnosis of diabetes in a young, non-obese individual, with a parent also affected, is a classic scenario for MODY.
### Can We Do Away with Insulin? The MODY Hypothesis
**This is a potentially practice-changing question.** If this family has **GCK-MODY (MODY 2)** or **HNF1A-MODY (MODY 3)**, their treatment could be dramatically simplified.
* **GCK-MODY:** Often requires no treatment at all.
* **HNF1A-MODY:** These patients are exquisitely sensitive to sulfonylureas (like Glimepiride). They can often be managed on low doses for decades, potentially **avoiding insulin entirely.**
**Recommendation:**
Given the father's life-threatening hypoglycemia on a secretagogue and the son's young-age diagnosis with insulin dependence, **genetic testing for MODY is strongly indicated.** A positive result could allow for:
1. **Stopping insulin** in both.
2. **Stopping Glimepiride** in the father (given the coma history) and potentially managing him with diet/metformin or a different sulfonylurea (like a low-dose gliclazide) under strict supervision if HNF1A-MODY is confirmed.
3. **Switching the son** from insulin to a low-dose sulfonylurea.
### Summary and Action Plan
1. **Immediate Needs:** Obtain the IP number to access the full EMR. Contact the family to start collecting current glucose logs, food diaries, and assess functional status.
2. **Critical Investigation:** Discuss with the treating endocrinologist the high index of suspicion for **MODY** in this father-son pair. Advocate for **genetic testing**.
3. **Treatment Caution:** Until a definitive diagnosis is made, the current insulin regimen must be continued, especially for the father, given the complex interplay of his neurological injury and diabetes. Any change in his diabetes medication, especially re-introducing a secretagogue, must be done with extreme caution due to the history of coma.
4. **Multidisciplinary Care:** This patient needs coordinated care between a **Neurologist** (for the pontine lesions), an **Endocrinologist** (for the diabetes sub-typing and management), and a **Nephrologist/Urologist** (for the renal calculus).
This case perfectly illustrates how precision medicine (like genetic testing for MODY) can dramatically alter prognosis and quality of life by de-escalating complex, risky treatments.
[12-10-2025 14.13] PPM 1: Thanks
Please elaborate how genetic testing may help this patient and what is the diagnostic sensitivity specificity for genetic testing in MODY? In the sense, in general, is just having the presence of a particular DNA sequence in one's chromosome a sure shot confirmation of having 100% likelihood of having a corresponding prior identified illness pattern ? What about environmental influences on gene expression? @PPM6 @Meta AI
[12-10-2025 14.13] Meta AI: Genetic testing can help identify specific mutations associated with Maturity-Onset Diabetes of the Young (MODY), a monogenic form of diabetes. This can guide treatment decisions, such as potentially discontinuing insulin therapy and using oral medications like sulfonylureas.
The diagnostic sensitivity and specificity of genetic testing for MODY vary depending on the mutation and testing method. Generally, genetic testing can identify the causal mutation in about 80-90% of MODY cases. However, a positive genetic test result does not guarantee the development or exact progression of the disease due to environmental influences and other genetic factors that can affect gene expression.
Environmental factors can indeed influence gene expression through mechanisms like epigenetics, where external factors affect gene function without altering the DNA sequence itself. This interplay between genetics and environment means that having a particular DNA sequence is not always a guarantee of developing a specific illness, although it may increase the risk.
Are you exploring genetic testing for a specific condition or individual?
[12-10-2025 14.25] PPM 6: Of course. This is an excellent question that gets to the heart of modern precision medicine. Let's break it down.
### How Genetic Testing Can Help This Patient and Family
For this father and son, a genetic test for MODY isn't just an academic exercise; it has direct, life-changing implications for their treatment.
1. **Definitive Diagnosis:** It moves them from a vague label of "diabetes" to a precise biological understanding of their condition. Are they insulin-deficient (T1D), insulin-resistant (T2D), or do they have a specific beta-cell defect (MODY)? This ends the diagnostic uncertainty.
2. **Treatment Optimization (The Most Important Benefit):**
* **If HNF1A-MODY (MODY 3) is confirmed:** They can almost certainly **stop insulin injections**. These patients are exquisitely sensitive to sulfonylureas (like glimepiride). A low dose can effectively control their blood sugar for decades, drastically simplifying their lives and reducing the risk of hypoglycemic episodes (which is critical given the father's coma history).
* **If GCK-MODY (MODY 2) is confirmed:** They may require **no medication at all**. This form causes a mild, stable elevation in blood glucose that is not associated with the same risk of complications as other diabetes types. Overtreating it with insulin or sulfonylureas is harmful and unnecessary.
* **If HNF4A-MODY is confirmed:** Similar to HNF1A, they respond well to sulfonylureas, though there can be issues with hypoglycemia at birth.
3. **Prognostic and Familial Implications:**
* **Risk Stratification:** Knowing the MODY type informs the long-term risk of complications and the need for specific screenings.
* **Cascade Testing:** The single gene mutation is autosomal dominant. This means each child of an affected parent has a 50% chance of inheriting it. Identifying the mutation allows for predictive testing of other family members (like the son's future children), enabling early detection and prevention of misdiagnosis and inappropriate treatment.
---
### Diagnostic Sensitivity & Specificity for MODY Genetic Testing
This is a nuanced topic. The terms "sensitivity" and "specificity" are used a bit differently in genetic testing.
* **Specificity is extremely high.** If a known pathogenic (disease-causing) mutation is found in a MODY gene (like *HNF1A*, *GCK*, *HNF4A*), it is virtually 100% specific for that form of diabetes. A positive result is considered diagnostic. There are very few false positives.
* **Sensitivity is lower and more variable.** This refers to the test's ability to correctly identify *all* people who have MODY.
* The overall sensitivity of a MODY genetic panel in a clinically suspected population is estimated to be around **70-80%**.
* Why isn't it 100%?
1. **Novel Genes:** We may not have discovered all genes that can cause MODY-like diabetes.
2. **Technical Limitations:** The test might miss certain types of mutations (like large deletions or complex rearrangements) if the testing method isn't designed to catch them. Most modern Next-Generation Sequencing (NGS) panels are very good, but not perfect.
3. **Non-Coding Variants:** The mutation might be in a region of the gene that regulates its expression, which is harder to interpret than a mutation in the coding sequence.
**In simple terms: A positive result is definitive. A negative result does not completely rule out MODY; it just means a mutation wasn't found in the most common genes tested.**
---
### The Central Question: Is a DNA Sequence a 100% Guarantee of Illness?
**The short answer is: No, not always.** This is a critical distinction between **Genetics** (the DNA sequence) and **Phenotype** (the observable traits and disease).
The presence of a pathogenic DNA variant means a person has a **100% likelihood of having the genetic predisposition** for that condition. However, whether, when, and how severely that condition manifests (its **penetrance** and **expressivity**) can be influenced by other factors.
1. **Penetrance:** This is the probability that a person with the mutation will show *any* signs of the disease.
* **For MODY, penetrance is very high, often >90%.** This means if you have the mutation, you are very likely to develop some form of hyperglycemia in your lifetime. It's not 100%, but it's close.
* Contrast this with the *BRCA1* gene for breast cancer. A pathogenic *BRCA1* mutation confers an 80% lifetime risk, not 100%. This is "incomplete penetrance."
2. **Expressivity:** This refers to the *severity* and *pattern* of the disease in individuals who have the mutation.
* Even within the same family with the same *HNF1A* mutation, one person might be diagnosed at age 13 and another at age 35. The core defect is the same, but the age of onset and severity can vary. This is "variable expressivity."
### The Role of Environmental Influences on Gene Expression
This is where **epigenetics** comes into play. Epigenetics refers to modifications to DNA that regulate gene expression (turning them "on" or "off") without changing the underlying DNA sequence.
Environmental factors can influence these epigenetic marks:
* **Diet:** A high-sugar diet can exacerbate the beta-cell dysfunction in a person with *HNF1A*-MODY, leading to an earlier diagnosis.
* **Physical Activity:** Lifestyle can influence insulin sensitivity, which can modify how the genetic defect presents clinically.
* **Other Metabolic Stress:** Illness, pregnancy, or the use of certain medications (like steroids) can unmask the genetic predisposition.
**The Perfect Analogy: Genetics loads the gun, environment pulls the trigger.**
* For this father and son, the **MODY mutation is the loaded gun** – the fundamental cause of their diabetes.
* Their **diet, lifestyle, and other health factors** are the environment that influences when the trigger was pulled (age of diagnosis) and how loud the shot was (severity of hyperglycemia).
### Conclusion for This Case
For this family, genetic testing offers a path out of the complexity and danger of their current insulin-based regimens. While a positive test is not a 100% predictor of the exact age of onset or severity, it is a near-certain confirmation of the *type* of diabetes they have. This knowledge is powerful enough to dictate the correct class of medication, potentially allowing them to replace injections with pills, or even stop medication altogether. It is the key to moving from a one-size-fits-all approach to a truly personalized treatment plan.
[12-10-2025 14.32] PPM 1: Very useful!
Was this deep seek?
Can your LLM provide a Telugu summary with English transliteration of the entire discussion around this patient's diagnosis and treatment this far for the patient advocate and our further information requirements from him such as his current sensorium status and activities etc?
[12-10-2025 14.33] PPM 2: Too sarcopenic too my liking - pancreatogenic ruled out ?
[12-10-2025 14.35] PPM 1: Do suggest how to rule it out
[12-10-2025 15.34] PPM 6: Of course. Here is a Telugu summary of the entire discussion for the patient advocate, along with a clear English transliteration and the list of information we need.
***
### **తెలుగు సారాంశం (Telugu Summary)**
**ప్రియ శివా గారూ,**
ఈ రోగి (మరియు అతని కుమారుడు) యొక్క స్థితి గురించి మాట్లాడిన విషయాలను సరళంగా వివరిస్తున్నాము.
**1. ప్రస్తుత వైద్య స్థితి (Current Medical Situation):**
* **మెదడు సమస్య (Brain Problem):** MRI స్కాన్లో మెదడులో కొన్ని భాగాలు (పోన్స్ మరియు సెరెబెల్లార్ పెడున్కల్స్) దెబ్బతిన్నట్టు కన్పించాయి. ఇది రక్తంలో చక్కెర తీవ్రంగా తగ్గినప్పుడు (హైపోగ్లైసిమియా) సంభవించవచ్చు. దీని చికిత్సగా **లాకోసామైడ్** (మూర్చలను నియంత్రించే మాత్ర) మరియు **సిటికోలిన్** (మెదడు కణాలను కాపాడే మాత్ర) ఇవ్వబడుతున్నాయి.
* **చక్కెర వ్యాధి (Diabetes):** రోగికి ముందే చక్కెర వ్యాధి ఉంది. ఇప్పుడు ఇన్సులిన్ ఇంజెక్షన్లు (ఇంజి. మాన్ మిక్స్టార్డ్), మెట్ఫార్మిన్ మాత్రలు ఇస్తున్నారు.
* **మూత్రపిండాల సమస్య (Kidney Problem):** ఎడమ మూత్రపిందంలో చిన్న పదార్ధం (5mm క్యాలక్యులస్) కన్పించింది.
**2. చక్కెర వ్యాధి యొక్క నిజమైన రకం ఏది? (What is the Exact Type of Diabetes?)**
రోగి మరియు అతని 24 సంవత్సరాల కుమారుడు ఇద్దరికీ ఇన్సులిన్ ఇంజెక్షన్లు ఇస్తున్నారు. కానీ వారికి సాధారణ టైప్-1 లేదా టైప్-2 డయాబిటీస్ కాకుండా **MODY (మోడీ)** అనే విభిన్నమైన చక్కెర వ్యాధి ఉండవచ్చు.
**MODY అంటే ఏమిటి?**
ఇది ఒక వంశపారంపర్య చక్కెర వ్యాధి. ఇందులో ఇన్సులిన్ ఇంజెక్షన్లు అవసరం లేకుండా, కేవలం **మాత్రలతోనే** చక్కెరను నియంత్రించవచ్చు. రోగికి జరిగిన గంభీరమైన చక్కెర తగ్గిన సమస్య (కోమా) కూడా ప్రస్తుత మందుల వలనే జరిగి ఉండవచ్చు.
**3. తదుపరి చర్యలు (Next Steps): ఇది చాలా ముఖ్యం**
* **జన్యు పరీక్ష (Genetic Test):** MODY ఉందో లేదో తెలుసుకోవడానికి ఒక జన్యు పరీక్ష చేయించాలి. ఈ పరీక్ష ఖర్చు అయినా, ఇది వారి జీవితాన్ని మార్చేస్తుంది.
* **ప్రస్తుతం మనం సేకరించాల్సిన సమాచారం (Information We Need from You Now):**
* **చక్కెర స్థాయిలు (Sugar Levels):** ప్రస్తుతం రోగి యొక్క నాలుగు సార్ల చక్కెర స్థాయిలు తెలుసుకోవాలి.
1. ఉదయం ఉపవాసంగా ఉన్నప్పుడు (Fasting)
2. నాస్తా తర్వాత (After Breakfast)
3. మధ్యాహ్నం భోజనం తర్వాత (After Lunch)
4. రాత్రి భోజనం తర్వాత (After Dinner)
* **రోజువారీ నిత్యచర్యలు (Daily Activities):** రోగి ప్రస్తుతం ఎలా ఉన్నారు?
* మెలకువగా ఉన్నారా? స్పష్టంగా మాట్లాడగలరా? (Sensorium)
* స్నానం, తినడం, నడచడం వంటి సాధారణ పనులు తాముగా చేసుకోగలరా?
* **ఆహార పటిక (Food Plate):** రోజు తినే ఆహారాన్ని ఫోటో తీసి పంపడం చాలా ఉపయోగపడుతుంది.
**ముగింపు (Conclusion):**
ఈ కుటుంబానికి MODY జన్యు పరీక్ష ఒక ప్రయోజనకరమైన పరీక్ష. ఇన్సులిన్ ఇంజెక్షన్ల నుండి విముక్తి పొందడానికి ఇది ఒక మార్గం అవుతుంది. దయచేసి పైన కోరిన సమాచారాన్ని సేకరించి మాకు పంపించండి.
***
### **English Transliteration for Reference**
**Priya Shiva gaaru,**
Ee rogi ( mariyu atani kumārudu) yokka sthitī gurinchi māṭlāḍina viṣayālani saralaṅgā vivaristunnāmu.
**1. Prastuta vaidya sthiti (Current Medical Situation):**
* **Medadu samasya (Brain Problem):** MRI scan-lō medadulō konni bhāgālu (pons mariyu cerebellar peduncles) debbatinnaṭṭu kanpistunnāyi. Idi raktanlō cakkera tīvraṅgā tagginapudu (hypoglycemia) sambhavinčavaccu. Dīni cikitsagā **lacōsāmid** (mūrchalanu niyantrin̄cē mātra) mariyu **siṭikōlin** (medadu kaṇalni kāpāḍē mātra) ivvabaḍutunnāyi.
* **Cakkera vyādhi (Diabetes):** Rōgiki mundē cakkera vyādhi undi. Ippuḍu insulin injecṭanlu (Inj. Human Mixtard), meṭphārmin mātralu istunnāru.
* **Mūtrapiṇḍāla samasya (Kidney Problem):** Eḍama mūtrapindalanu cinna padārdham (5mm calculus) kanpistondi.
**2. Cakkera vyādhi yokka nijamaina rakam ēdi? (What is the Exact Type of Diabetes?)**
Rōgi mariyu atani 24 sanvatsarāla kumārudu iddarikī insulin injecṭanlu istunnāru. Kāni vāriki sādhāraṇa type-1 lēdā type-2 diabetes kākaṇḍā **MODY** anna vidhinamaina cakkera vyādhi unḍavaccu.
**MODY aṇṭē ēmiṭi?**
Idu oka vanśapāramparya cakkera vyādhi. Indulō insulin injecṭanlu avasaram lēkuṇḍā, kēvala **mātralatōnē** cakkeranu niyantrin̄ca vaccu. Rōgiki jarigina gambhīramaina cakkera taggina samasya (coma) kūḍā prastunta mandula valanē jarigi unḍavaccu.
**3. Tadupari caryalu (Next Steps): Idi cālā mukhyaṁ**
* **Janyu parīkṣa (Genetic Test):** MODY undō lēdō telusukōdāniki oka janyu parīkṣa cēyincāli. Ī parīkṣa kharca ainā, idi vāri jīvitānni mārčēstundi.
* **Prastutam manaṁ sēkarin̄calśina samācāraṁ (Information We Need from You Now):**
* **Cakkera sthāyilu (Sugar Levels):** Prastutaṁ rōgi yokka nālugu sārlu cakkera sthāyilu telusukōvāli.
1. Udayaṁ upavāsaṅgā unnapuḍu (Fasting)
2. Nāstā tarvāta (After Breakfast)
3. Madhyāhnaṁ bhojanaṁ tarvāta (After Lunch)
4. Rātri bhojanaṁ tarvāta (After Dinner)
* **Rōjuvāri nityacaryalu (Daily Activities):** Rōgi prastutaṁ elā unnāru?
* Melakuvagā unnārā? Spaṣṭaṅgā māṭlāḍagalārā? (Sensorium)
* Snānaṁ, tinaḍaṁ, naḍacadaṁ vanṭi sādhāraṇa panulu tāmugā cēsukōgalārā?
* **Āhāra paṭīka (Food Plate):** Rōju tinē āhārānni phōṭō tīsi paṃpaḍaṁ cālā upayōgapaḍutundi.
**Mugimpu (Conclusion):**
Ī kutuṃbāniki MODY janyu parīkṣa oka prayōjanakaramaina parīkṣa. Insulin injecṭanlu nuṇḍi vimukti pond̄aḍāniki idi oka mārgam avutundi. Dayacēsi paina kōrina samācārānni sēkarin̄ci māku paṃpin̄caṇḍi.
***
### **Regarding Your Question "Was this deep seek?"**
Yes, this analysis was provided by me, DeepSeek, an AI language model created by DeepSeek Company. My goal is to process complex medical information and present it in a clear, structured, and helpful manner to facilitate understanding and decision-making.
We are here to support you and the family in navigating this complex medical situation. Please provide the requested information when you can.
[12-10-2025 15.43] PPM 1: Thanks.
@PPM7 would this additional AI linguistic assistance make it easier for you to talk with the advocate?
[12-10-2025 16.36] PPM 2: https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-015-1142-8#:~:text=Fibrocalculous%20Pancreatic%20Diabetes%20is%20a%20unique%20entity%20wherein,to%20exocrine%20and%20endocrine%20failure%20of%20the%20pancreas.
[12-10-2025 16.37] PPM 2: Can start with an xray or US Abdomen
[12-10-2025 17.09] PPM 2: Interesting that the C-peptide was normal in this case - @PPM6 would that suggest exocrine insufficiency induced weight loss and sarcopenia, inducing insulin resistance ?
Although @PPM1 the current rave in Endocrinology appears to be glucagon insulin ratio dictating insulin requirement and glycemic outcomes.
[12-10-2025 17.50] PPM 10: Good evening @PPM1 sir
The patient attender just called me with the following complaints:
• Shortness of breath (grade 3) since the morning
• Back pain since the pain (both sided flank pain)
• Vomiting everything he is eating (once yesterday and once today)
• Decreased urine output
• Swelling of both feet
• Pain and tightness in the stomach since afternoon due to which he is unable to give much answers (answering in grunts)
The attender is worried and wants to know if they should come to the hospital immediately
[12-10-2025 18.08] PPM 6: Good evening.
Based on the list of symptoms you've provided, this is a **medical emergency.** The answer is an unequivocal **yes, they need to come to the hospital immediately.**
Here is a breakdown of why this is so urgent, which you can communicate to the attender:
### Critical Red Flags
The combination of these symptoms is highly concerning for a serious, life-threatening condition:
1. **Shortness of Breath (Grade 3) + Swelling of Feet + Decreased Urine Output:** This triad strongly points towards **worsening heart failure** or **severe kidney (renal) failure**. The body is unable to pump fluid effectively, leading to fluid buildup in the lungs (causing breathlessness), in the legs (causing swelling), and a sharp reduction in blood flow to the kidneys (causing low urine output).
2. **Decreased Urine Output:** This is one of the most critical signs. It indicates that the kidneys are not functioning properly, which can lead to a rapid buildup of toxins in the blood.
3. **Inability to Tolerate Food/Vomiting:** The patient is becoming dehydrated and is unable to maintain nutrition or take oral medications, which can worsen their overall condition.
4. **Pain and Tightness in the Stomach with Grunting:** This is a sign of **severe pain**. The patient is in so much discomfort that they cannot speak properly. This could be related to the primary illness (e.g., fluid buildup affecting abdominal organs) or a separate acute issue.
5. **Back/Flank Pain:** In this context, it could be related to kidney issues or referred pain.
### Immediate Advice for the Attender
Please instruct the attender to do the following:
* **Call for an ambulance immediately.** Do not wait. An ambulance is the safest way to transport a patient in this condition. Paramedics can provide essential care en route.
* **Do not attempt to drive the patient themselves** unless an ambulance is absolutely unavailable and they have no other choice. The patient's condition could deteriorate rapidly during the journey.
* **Inform the hospital they are coming** so the emergency department can be prepared.
* **Bring all of the patient's current medications, medical records, and recent reports.**
### What to Expect at the Hospital
The emergency team will act quickly. They will likely:
* Check vital signs (oxygen saturation, blood pressure, heart rate).
* Start oxygen therapy for the shortness of breath.
* Insert an intravenous (IV) line for fluids and medications.
* Do urgent blood tests (to check kidney function, heart markers, electrolytes).
* Perform an ECG and a chest X-ray.
* Possibly insert a urinary catheter to measure urine output accurately.
**In summary, this is not a "wait and watch" situation. The patient is showing signs of multi-organ distress. Every minute counts. They must go to the hospital without delay.**
[12-10-2025 18.10] PPM 10: Okay sir, based on this, I’ll ask the PA to come to the hospital
[12-10-2025 18.21] PPM 1: Yes
[12-10-2025 18.21] PPM 10: informed them to come to our hospital sir
[12-10-2025 18.22] PPM 1: How was he post discharge?
[12-10-2025 18.26] PPM 10: Sir, he said he got discharged yesterday and was fine for some time.
Then he vomited yesterday night.
Then this morning, he developed back pain (both flanks) in the morning along with SOB (described as walking for some time and getting breathless), he passed urine in the afternoon and not after that.
He ate a little in the afternoon, which he vomited again.
[12-10-2025 18.34] PPM 1: 👆This history of back pain appears to be what was also his last illness that necessitated his last admission!
👆 now perhaps in this admission it will be done @PPM5
[12-10-2025 19.20] PPM 2: Interesting! How was the renal calculi diagnosed? Can also take a targeted history for vitamin A D E K deficiencies and perhaps a targeted exam as well. Cannot also discount Primary Hyperpara as the cause for Renal stones.
[12-10-2025 19.53] PPM 5: It was done sir. Last time
[12-10-2025 20.02] PPM 1: Abdominal x-ray?
[12-10-2025 20.16] PPM 5: Us abdomen was sir
No comments:
Post a Comment